Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to
The manufacturer of the testosterone injection, Delatestryl, is facing a class action lawsuit alleging that the company failed to warn about the risk of cardiovascular events, including blood clot, stroke, heart attack, and death. There have been global, mounting concerns about the risks of testosterone replacement drugs after regulators began investigating the issue; the safety reviews were prompted by two studies showing a higher risk of cardiovascular issues in men who use testosterone products. Port Washington, New York (PRWEB) July 29, 2014 Parker Waichman LLP, a national law firm ded
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 313
- Bankruptcy 44
- Business 134
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4